Specific associations between plasma biomarkers and postmortem amyloid plaque and tau tangle loads
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Erschienen in
-
Specific associations between plasma biomarkers and postmortem amyloid plaque and tau tangle loads ; day:13 ; month:03 ; year:2023 ; extent:16
EMBO molecular medicine / European Molecular Biology Organization ; (13.03.2023) (gesamt 16)
- Urheber
-
Salvadó, Gemma
Ossenkoppele, Rik
Ashton, Nicholas J.
Beach, Thomas G.
Serrano, Geidy E.
Reiman, Eric M.
Zetterberg, Henrik
Mattsson-Carlgren, Niklas
Janelidze, Shorena
Blennow, Kaj
Hansson, Oskar
- DOI
-
10.15252/emmm.202217123
- URN
-
urn:nbn:de:101:1-2023031314191276032603
- Rechteinformation
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
14.08.2025, 10:49 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Salvadó, Gemma
- Ossenkoppele, Rik
- Ashton, Nicholas J.
- Beach, Thomas G.
- Serrano, Geidy E.
- Reiman, Eric M.
- Zetterberg, Henrik
- Mattsson-Carlgren, Niklas
- Janelidze, Shorena
- Blennow, Kaj
- Hansson, Oskar
Ähnliche Objekte (12)
Fluid biomarkers in Alzheimer’s disease – current concepts
Moving fluid biomarkers for Alzheimer’s disease from research tools to routine clinical diagnostics
Mass Spectrometric Analysis of Cerebrospinal Fluid Ubiquitin in Alzheimer's Disease and Parkinsonian Disorders
Cerebro-spinal fluid biomarker levels: phosphorylated tau (T) and total tau (N) as markers for rate of progression in Alzheimer’s disease
Plasma glial fibrillary acidic protein detects Alzheimer pathology and predicts future conversion to Alzheimer dementia in patients with mild cognitive impairment
Cerebrospinal fluid tau, neurogranin, and neurofilament light in Alzheimer's disease
Cerebrospinal fluid N-224 tau helps discriminate Alzheimer’s disease from subjective cognitive decline and other dementias
Increasing the reproducibility of fluid biomarker studies in neurodegenerative studies
Publisher Correction: Increasing the reproducibility of fluid biomarker studies in neurodegenerative studies
Cerebral Aβ deposition precedes reduced cerebrospinal fluid and serum Aβ42/Aβ40 ratios in the App NL−F/NL−F knock-in mouse model of Alzheimer’s disease
Neuroligin-1 in brain and CSF of neurodegenerative disorders: investigation for synaptic biomarkers
The accuracy and robustness of plasma biomarker models for amyloid PET positivity
Fluid biomarkers in Alzheimer’s disease – current concepts
Moving fluid biomarkers for Alzheimer’s disease from research tools to routine clinical diagnostics
Mass Spectrometric Analysis of Cerebrospinal Fluid Ubiquitin in Alzheimer's Disease and Parkinsonian Disorders
Cerebro-spinal fluid biomarker levels: phosphorylated tau (T) and total tau (N) as markers for rate of progression in Alzheimer’s disease
Plasma glial fibrillary acidic protein detects Alzheimer pathology and predicts future conversion to Alzheimer dementia in patients with mild cognitive impairment
Cerebrospinal fluid tau, neurogranin, and neurofilament light in Alzheimer's disease
Cerebrospinal fluid N-224 tau helps discriminate Alzheimer’s disease from subjective cognitive decline and other dementias
Increasing the reproducibility of fluid biomarker studies in neurodegenerative studies
Publisher Correction: Increasing the reproducibility of fluid biomarker studies in neurodegenerative studies
Cerebral Aβ deposition precedes reduced cerebrospinal fluid and serum Aβ42/Aβ40 ratios in the App NL−F/NL−F knock-in mouse model of Alzheimer’s disease
Neuroligin-1 in brain and CSF of neurodegenerative disorders: investigation for synaptic biomarkers
The accuracy and robustness of plasma biomarker models for amyloid PET positivity
Fluid biomarkers in Alzheimer’s disease – current concepts
Moving fluid biomarkers for Alzheimer’s disease from research tools to routine clinical diagnostics
Mass Spectrometric Analysis of Cerebrospinal Fluid Ubiquitin in Alzheimer's Disease and Parkinsonian Disorders
Cerebro-spinal fluid biomarker levels: phosphorylated tau (T) and total tau (N) as markers for rate of progression in Alzheimer’s disease
Plasma glial fibrillary acidic protein detects Alzheimer pathology and predicts future conversion to Alzheimer dementia in patients with mild cognitive impairment
Cerebrospinal fluid tau, neurogranin, and neurofilament light in Alzheimer's disease
Cerebrospinal fluid N-224 tau helps discriminate Alzheimer’s disease from subjective cognitive decline and other dementias
Increasing the reproducibility of fluid biomarker studies in neurodegenerative studies
Publisher Correction: Increasing the reproducibility of fluid biomarker studies in neurodegenerative studies
Cerebral Aβ deposition precedes reduced cerebrospinal fluid and serum Aβ42/Aβ40 ratios in the App NL−F/NL−F knock-in mouse model of Alzheimer’s disease
Neuroligin-1 in brain and CSF of neurodegenerative disorders: investigation for synaptic biomarkers